

JointHealth™

Arthritis Medications Report Card

How does your province measure up?

The JointHealth™ Arthritis Medications Report Card is designed to help Canadians evaluate how their province measures up in terms of providing reimbursement access to medications approved for auto-immune (like rheumatoid arthritis) arthritis treatment.


Depending on where they live, Canadians living with an auto-immune arthritis may have fewer treatment options or have to “jump through more hoops” to qualify for reimbursement for the medication prescribed for them by their rheumatologist or other specialist.

The JointHealth™ Arthritis Medications Report Card highlights this inequality of treatment and now tracks three classes of medications used to treat auto-immune forms of arthritis: Biologic Response Modifiers (Biologics), subsequent entry biologics (SEBs) and Targeted small molecule medications (TSMMs).

If your province doesn't measure up, ACE encourages you to write and speak to your elected provincial or federal representative about the lack of equitable reimbursement access and patient/physician choice in treating auto-immune forms of arthritis.

How the points are scored

Arthritis Consumer Experts (ACE) ranks publicly funded medication formularies based on the number of medically necessary arthritis medications they list out of a possible 15.



Medications Chart : Updated November 2014

1st British Columbia (3rd in 2013, 2nd in 2012, 1st in 2011, 4th in 2010)

generic name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis (active disease)	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	This is a new medical term used to describe early disease not yet visible on X-ray.	Listed—CBC	In Trials	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC		Listed—CBC	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A		N/A	N/A	Declined	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Under Review		N/A	Under Review	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A		N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®)	Listed—CBC	Listed—CBC		Listed—CBC	Listed—CBC	Listed—CBC	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC		Listed—CBC	N/A	Listed—CBC	N/A	N/A
infliximab (Remicade®)	Listed—CBC	Listed—CBC		Listed—CBC	N/A	Listed—CBC	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A		N/A	N/A	N/A	N/A	Listed—CBC
tocilizumab (Actemra®)	Listed—CBC	N/A		N/A	Listed—CBC	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A		N/A	N/A	Under Review	N/A	N/A
SEB infliximab (Inflectra®)	Under Review	Under Review		N/A	N/A	Under Review	N/A	N/A
Tofacitinib citrate (Xeljanz®)	Under Review	N/A		N/A	N/A	N/A	N/A	N/A

1st Québec (3rd in 2013, 2nd in 2012, 2nd in 2011, 1st in 2010)

abatacept (Orencia®)	Listed—CBC	N/A	This is a new medical term used to describe early disease not yet visible on X-ray.	Listed—CBC	In Trials	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC		Under Review	Listed—CBC	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A		N/A	N/A	Under Review	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Under Review		N/A	Under Review	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A		N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®)	Listed—CBC	Listed—CBC		Listed—CBC	Listed—CBC	Listed—CBC	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC		Listed—CBC	N/A	Listed—CBC	N/A	N/A
infliximab (Remicade®)	Listed—CBC	Listed—CBC		Listed—CBC	Listed—CBC	Listed—CBC	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A		N/A	N/A	N/A	N/A	Under Review
tocilizumab (Actemra®)	Listed—CBC	N/A		N/A	Listed—CBC	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A		N/A	N/A	Listed—CBC	N/A	N/A
SEB infliximab (Inflectra®)	Under Review	Under Review		N/A	N/A	Under Review	N/A	N/A
Tofacitinib citrate (Xeljanz®)	Under Review	N/A		N/A	N/A	N/A	N/A	N/A

Medications Chart : Updated November 2014

generic name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis (active disease)	non-radiographic axial spondyloarthritis (not visible on X-ray)					

1st Saskatchewan (1st in 2013, 4th in 2012, 2nd in 2011, 2nd in 2010)

abatacept (Orencia®)	Listed—CBC	N/A	This is a new medical term used to describe early disease not yet visible on X-ray.	Listed—CBC	In Trials	N/A	N/A	N/A	
adalimumab (Humira®)	Listed—CBC	Listed—CBC		Listed—CBC	N/A	N/A	Declined	N/A	N/A
belimumab (Benlysta®)	N/A	N/A		N/A	N/A	Under Review	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Under Review		N/A	N/A	N/A	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A		N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®)	Listed—CBC	Listed—CBC		Listed—CBC	Listed—CBC	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC		Listed—CBC	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®)	Listed—CBC	Listed—CBC		Listed—CBC	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A		N/A	N/A	N/A	N/A	Listed—CBC	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A		N/A	Listed—CBC	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A		N/A	N/A	Under Review	N/A	N/A	N/A
SEB infliximab (Inflectra®)	Under Review	Under Review		N/A	N/A	Under Review	N/A	N/A	N/A
Tofacitinib citrate (Xeljanz®)	Under Review	N/A		N/A	N/A	N/A	N/A	N/A	N/A

1st Ontario (1st in 2013, 1st in 2012, 5th in 2011, 7th in 2010)

abatacept (Orencia®)	Listed—CBC	N/A	This is a new medical term used to describe early disease not yet visible on X-ray.	Listed—CBC	In Trials	N/A	N/A	N/A	
adalimumab (Humira®)	Listed—CBC	Listed—CBC		Listed—CBC	N/A	N/A	Declined	N/A	N/A
belimumab (Benlysta®)	N/A	N/A		N/A	N/A	Under Review	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Under Review		N/A	N/A	N/A	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A		N/A	N/A	N/A	N/A	N/A	Under Review
etanercept (Enbrel®)	Listed—CBC	Listed—CBC		Listed—CBC	Listed—CBC	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC		Listed—CBC	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®)	Listed—CBC	Listed—CBC		Listed—CBC	Listed—CBC	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A		N/A	N/A	N/A	N/A	Listed—CBC	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A		N/A	Listed—CBC	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A		N/A	N/A	Under Review	N/A	N/A	N/A
SEB infliximab (Inflectra®)	Under Review	Under Review		N/A	N/A	Under Review	N/A	N/A	N/A
Tofacitinib citrate (Xeljanz®)	Under Review	N/A		N/A	N/A	N/A	N/A	N/A	N/A

Medications Chart : Updated November 2014

generic name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis (active disease)	non-radiographic axial spondyloarthritis (not visible on X-ray)					

5th Manitoba (5th in 2013, 11th in 2012, 11th in 2011, 11th in 2010)

abatacept (Orencia®)	Listed—CBC	N/A	This is a new medical term used to describe early disease not yet visible on X-ray.	Under Review	In Trials	N/A	N/A	N/A	
adalimumab (Humira®)	Listed—CBC	Listed—CBC		Listed—CBC	Listed—CBC	Listed—CBC	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A		N/A	N/A	N/A	Under Review	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Under Review		N/A	Under Review	N/A	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A		N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®)	Listed—CBC	Listed—CBC		Unknown	Listed—CBC	N/A	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC		N/A	Listed—CBC	N/A	N/A	N/A	N/A
infliximab (Remicade®)	Listed—CBC	Listed—CBC		N/A	Listed—CBC	N/A	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A		N/A	N/A	N/A	N/A	Listed—CBC	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A		Listed—CBC	N/A	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A		N/A	Under Review	N/A	N/A	N/A	N/A
SEB infliximab (Inflectra®)	Under Review	Under Review		N/A	Under Review	N/A	N/A	N/A	N/A
Tofacitinib citrate (Xeljanz®)	Under Review	N/A		N/A	N/A	N/A	N/A	N/A	N/A

5th Nova Scotia (7th in 2013, 8th in 2012, 8th in 2011, 7th in 2010)

abatacept (Orencia®)	Listed—CBC	N/A	This is a new medical term used to describe early disease not yet visible on X-ray.	Listed—CBC	In Trials	N/A	N/A	N/A	
adalimumab (Humira®)	Listed—CBC	Listed—CBC		Listed—CBC	Listed—CBC	Listed—CBC	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A		N/A	N/A	N/A	Under Review	N/A	N/A
certolizumab pegol (Cimzia®)	Under Review	Under Review		N/A	Under Review	N/A	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A		N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®)	Listed—CBC	Listed—CBC		Listed—CBC	Listed—CBC	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC		N/A	Listed—CBC	N/A	N/A	N/A	N/A
infliximab (Remicade®)	Listed—CBC	Listed—CBC		N/A	Declined	N/A	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A		N/A	N/A	N/A	N/A	Listed—CBC	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A		Listed—CBC	N/A	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A		N/A	Under Review	N/A	N/A	N/A	N/A
SEB infliximab (Inflectra®)	Under Review	Under Review		N/A	Under Review	N/A	N/A	N/A	N/A
Tofacitinib citrate (Xeljanz®)	Under Review	N/A		N/A	N/A	N/A	N/A	N/A	N/A

Medications Chart : Updated November 2014

7th Alberta (6th in 2013, 5th in 2012, 4th in 2011, 2nd in 2010)

generic name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis (active disease)	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	This is a new medical term used to describe early disease not yet visible on X-ray.	Listed—ORC	In Trials	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC		Under Review	Listed—CBC	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A		N/A	N/A	Declined	N/A	N/A
certolizumab pegol (Cimzia®)	Under Review	Under Review		N/A	Under Review	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A		N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®)	Listed—CBC	Listed—CBC		Listed—CBC	Listed—CBC	Listed—CBC	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC		Listed—CBC	N/A	Listed—CBC	N/A	N/A
infliximab (Remicade®)	Listed—CBC	Listed—CBC		Listed—CBC	N/A	Listed—CBC	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A		N/A	N/A	N/A	N/A	Listed—CBC
tocilizumab (Actemra®)	Listed—CBC	N/A		Listed—CBC	Listed—CBC	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A		N/A	Under Review	N/A	N/A	N/A
SEB infliximab (Inflectra®)	Under Review	Under Review		N/A	Under Review	N/A	N/A	N/A
Tofacitinib citrate (Xeljanz®)	Under Review	N/A		N/A	N/A	N/A	N/A	N/A

8th New Brunswick (7th in 2013, 6th in 2012, 5th in 2011, 4th in 2010)

abatacept (Orencia®)	Listed—CBC	N/A	This is a new medical term used to describe early disease not yet visible on X-ray.	Listed—CBC	In Trials	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC		Under Review	Listed—CBC	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A		N/A	N/A	Under Review	N/A	N/A
certolizumab pegol (Cimzia®)	Declined	Under Review		N/A	Under Review	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A		N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®)	Listed—CBC	Listed—CBC		Listed—CBC	Listed—CBC	Listed—CBC	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC		Listed—CBC	N/A	Listed—CBC	N/A	N/A
infliximab (Remicade®)	Listed—CBC	Listed—CBC		Listed—CBC	N/A	Declined	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A		N/A	N/A	N/A	N/A	Listed—CBC
tocilizumab (Actemra®)	Listed—CBC	N/A		Listed—CBC	Listed—CBC	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A		N/A	Under Review	N/A	N/A	N/A
SEB infliximab (Inflectra®)	Under Review	Under Review		N/A	Under Review	N/A	N/A	N/A
Tofacitinib citrate (Xeljanz®)	Under Review	N/A		N/A	N/A	N/A	N/A	N/A

Medications Chart : Updated November 2014

8th

NIHB* (10th in 2013, 8th in 2012, 8th in 2011, 9th in 2010)

generic name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis	
		ankylosing spondylitis (active disease)	non-radiographic axial spondyloarthritis (not visible on X-ray)						
abatacept (Orencia®)	Listed—CBC	N/A	This is a new medical term used to describe early disease not yet visible on X-ray.	Listed—CBC	In Trials	N/A	N/A	N/A	
adalimumab (Humira®)	Listed—CBC	Listed—CBC		Listed—CBC	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A		N/A	N/A	Under Review	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Under Review		N/A	Under Review	N/A	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A		N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®)	Listed—CBC	Listed—CBC		Listed—CBC	Listed—CBC	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC		Listed—CBC	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®)	Listed—CBC	Declined		Declined	N/A	Declined	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A		N/A	N/A	N/A	N/A	Under Review	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A		N/A	Listed—CBC	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A		N/A	N/A	Under Review	N/A	N/A	N/A
SEB infliximab (Inflectra®)	Under Review	Under Review		Under Review	N/A	Under Review	N/A	N/A	N/A
Tofacitinib citrate (Xeljanz®)	Under Review	N/A		N/A	N/A	N/A	N/A	N/A	N/A

8th

Prince Edward Island (7th in 2013, 10th in 2012, 8th in 2011, 9th in 2010)

abatacept (Orencia®)	Listed—CBC	N/A	This is a new medical term used to describe early disease not yet visible on X-ray.	Listed—CBC	In Trials	N/A	N/A	N/A	
adalimumab (Humira®)	Listed—CBC	Listed—CBC		Under Review	Listed—CBC	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A		N/A	N/A	Under Review	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Under Review		N/A	Under Review	N/A	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A		N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®)	Listed—CBC	Listed—CBC		Listed—CBC	Listed—CBC	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC		Listed—CBC	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®)	Listed—CBC	Listed—CBC		Listed—CBC	N/A	Under Review	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A		N/A	N/A	N/A	N/A	Under Review	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A		N/A	Listed—CBC	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A		N/A	N/A	Under Review	N/A	N/A	N/A
SEB infliximab (Inflectra®)	Under Review	Under Review		Under Review	N/A	Under Review	N/A	N/A	N/A
Tofacitinib citrate (Xeljanz®)	Under Review	N/A		N/A	N/A	N/A	N/A	N/A	N/A

Medications Chart : Updated November 2014

11th Newfoundland and Labrador (10th in 2013, 6th in 2012, 5th in 2011, 4th in 2010)

generic name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis (active disease)	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	This is a new medical term used to describe early disease not yet visible on X-ray.	Listed—CBC	In Trials	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC		Under Review	Listed—CBC	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A		N/A	N/A	Under Review	N/A	N/A
certolizumab pegol (Cimzia®)	Under Review	Under Review		N/A	Under Review	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A		N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®)	Listed—CBC	Listed—CBC		Listed—CBC	Listed—CBC	Listed—CBC	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC		N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®)	Listed—CBC	Listed—CBC		N/A	Declined	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A		N/A	N/A	N/A	Listed—CBC	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A		Under Review	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A		N/A	Under Review	N/A	N/A	N/A
SEB infliximab (Inflectra®)	Under Review	Under Review		N/A	Under Review	N/A	N/A	N/A
Tofacitinib citrate (Xeljanz®)	Under Review	N/A		N/A	N/A	N/A	N/A	N/A

12th Yukon (12th in 2013, 12th in 2012, 12th in 2011, 12th in 2010)

abatacept (Orencia®)	Listed—CBC	N/A	This is a new medical term used to describe early disease not yet visible on X-ray.	Under Review	In Trials	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC		Under Review	Listed—CBC	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A		N/A	N/A	Under Review	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Under Review		N/A	Under Review	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A		N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®)	Listed—CBC	Listed—CBC		Under Review	Listed—CBC	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC		N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®)	Listed—CBC	Listed—CBC		N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A		N/A	N/A	N/A	Under Review	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A		Under Review	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A		N/A	Under Review	N/A	N/A	N/A
SEB infliximab (Inflectra®)	Under Review	Under Review		N/A	Under Review	N/A	N/A	N/A
Tofacitinib citrate (Xeljanz®)	Under Review	N/A		N/A	N/A	N/A	N/A	N/A

Glossary

Declined: The formulary does not reimburse patients prescribed this medication.

In Trials: This medication is undergoing testing for use in treating this disease type.

Listed — CBC: Each province and territory has a process by which medications that are not normally included in the provincial, territorial or federal drug benefit lists are covered (or reimbursed). Approval of this drug is granted on a case-by-case basis.

Listed — ORC: The medication is listed, but the criteria are not supported by medical evidence. Arthritis Consumer Experts considers these overly restrictive criteria (ORC) unacceptable.

N/A: Not Applicable. No Notice of Compliance (or NOC) has been issued for this medication for this form of arthritis.

Under Review: This drug has been approved by Health Canada for this disease type and the province is considering whether patients should be reimbursed for it.

Unknown: There is no public information available.

CDR: The Common Drug Review (CDR) is part of the Canadian Agency for Drugs and Technologies in Health. The Common Drug Review (CDR) conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec). (<http://cadth.ca/index.php//cdr>)

The JointHealth™
Report Card
is updated
monthly online



bit.ly/ReportCard2014

A note about the Report Card:

Because provincial formularies change frequently, we encourage you to contact the Ministry of Health in your province with questions you may have about medication listings of concern to you.

Disclaimer

The material contained in this or any other ACE publication is provided for general information only. It should not be relied on to suggest a course of treatment for a particular individual or as a substitute for consultation with qualified health professionals who are familiar with your individual medical needs. If you have any healthcare related questions or concerns, you should contact your physician. Never disregard medical advice or delay in seeking it because of something you have read in any ACE publication.

Discover JointHealth™ online:



www.jointhehealth.org



<http://bit.ly/YouTubeJointHealth>



www.facebook.com/ACEJointHealth



www.twitter.com/ACEJointHealth

Discover Arthritis Broadcast Network online:



ArthritisBroadcastNetwork.org



<http://bit.ly/YouTubeABN>



www.facebook.com/ArthritisBroadcastNetwork



www.twitter.com/ArthritisNetwrk

Discover the apps



Got arthritis?

We have a free app to help you!
<http://bit.ly/GetArthritisID>

Treat arthritis?

We have a free app to help you!
<http://bit.ly/GetArthritisIDPRO>



Arthritis Consumer Experts™

#200A 1228 Hamilton Street,
Vancouver BC V6B 6L2

t: 604.974.1366

e: feedback@jointhehealth.org

www.jointhehealth.org